Earnings call: GSK reports strong Q3 growth, optimistic for 2024

By: Investing.com

Nov 14 2024
6
326 Views

Earnings call: GSK reports strong Q3 growth, optimistic for 2024

GSK (GlaxoSmithKline (NYSE:GSK) PLC) has reported a solid performance in its third-quarter earnings call, with CEO Emma Walmsley announcing a 9% sales growth and a 19% profit growth year-to-date. The… [+69425 chars]

Earnings call: GSK reports strong Q3 growth, optimistic for 2024

Cherry T. Thomas, M.D., Joins Wugen as Chief Medical Officer, Bringing Cell Therapy Expertise Across Clinical Development, Regulatory, and Medical Affairs as the Company Embarks on a Pivotal Trial for its Investigational, Allogeneic CD7-Targeted CAR-T Cel

Reviewing Psyence Biomedical (NASDAQ:PBM) & Harmony Biosciences (NASDAQ:HRMY)

Biopreservation Market to Reach Market Valuation of USD 20.54 Billion by 2031 | SkyQuest Technology

Majority of Children With Spinal Muscular Atrophy (SMA) Treated With Genentech's Evrysdi Are Able to Sit, Stand and Walk Independently, Two-Year Data Demonstrate

For Girls to Succeed in STEM, Confidence Matters as Much as Competence

Psyence Group Enters into Debt-for-Equity Swap Agreement with its NASDAQ-Listed Associate, Psyence Biomedical

Get Ready for a Catastrophic Four Years for Public Health

Nektar Therapeutics (NASDAQ:NKTR) Coverage Initiated at Piper Sandler

Nektar Therapeutics (NASDAQ:NKTR) Receives $2.33 Average Price Target from Analysts

Zenith Labs: Embracing a Holistic Approach to Anti-Aging

Metagenomi Presents Novel, Highly Specific and Efficient Adenine Base Editors for Broad Genome Editing at ESGCT

Share this page

Guest Posts by Easy Branches

anchor links ads by Easy Branches

Earnings call: GSK reports strong Q3 growth, optimistic for 2024

Related